Unlike testing focused only on the two best-known hereditary breast cancer genes, BRCA1 and BRCA2, multigene panels analyze numerous genes at the same time. These panels can identify variants in genes such as ATM, CHEK2 and PALB2, among others, that may increase breast cancer risk but do not always carry the extremely high lifetime risk associated with some BRCA1 or BRCA2 alterations. The clinical challenge is that risk is not uniform across these genes. It can depend on the specific variant, family history, age, reproductive history and other factors. A pathogenic variant is not a diagnosis of cancer; it is a molecular warning that can influence the intensity and timing of surveillance.

The researchers focused on women who fell into two clinically important categories. The first group carried pathogenic variants in genes generally classified as conferring moderate breast cancer risk. The second group did not necessarily have a high-risk genetic finding but had an empirically increased risk, meaning that their estimated risk was elevated on the basis of personal or family history, prior breast abnormalities or formal risk calculations. These risk models combine demographic and clinical variables to estimate the probability of developing breast cancer over a defined period or across a lifetime. In practice, women in either group may be advised to begin screening earlier, undergo annual magnetic resonance imaging in addition to mammography, or receive more specialized counseling.

The study addresses a gap between risk communication and preventive action. After genetic counseling, women may understand that screening is important, yet maintaining a schedule can be difficult. Mammography requires repeated appointments, while breast magnetic resonance imaging is more expensive, takes longer and usually involves intravenous contrast. MRI also detects more suspicious areas than mammography, which can lead to additional imaging or biopsies even when cancer is not present. These practical and psychological burdens can affect adherence. Some women may also misunderstand the meaning of a moderate-risk result, interpreting it either as a guarantee that cancer will develop or as a finding too weak to justify intensive surveillance.

Adherence is particularly complex because recommended screening is not identical for every patient. Mammography uses low-dose X-rays to identify structural changes such as masses, distortions and microcalcifications. MRI, by contrast, tracks the movement of contrast material through breast tissue and can reveal patterns of abnormal blood supply associated with tumors. Dense breast tissue can make mammographic interpretation more difficult, while MRI may detect lesions that mammography misses. For women with inherited susceptibility or a calculated lifetime risk above commonly used clinical thresholds, combining these techniques can improve the chance of detecting cancer at an earlier stage. The benefit, however, depends on completing examinations at the recommended intervals rather than attending sporadically.

By examining women after multigene panel testing, the research captures what happens beyond the moment of disclosure. Genetic testing is often portrayed as a decisive event: a result arrives, risk is explained and a surveillance plan is created. Real-world care is less linear. Results may be delivered through different clinical services, and follow-up can involve primary-care physicians, genetic counselors, breast specialists, radiologists and insurers. A patient may receive a recommendation for annual MRI but encounter scheduling delays, cost barriers or uncertainty about which clinician is responsible for ordering the scan. The study’s focus on actual screening behavior therefore offers a practical test of whether genetic information is being converted into sustained preventive care.

The findings carry implications for precision medicine, which seeks to tailor healthcare to a person’s biological and clinical characteristics. A genetic result is useful only when it produces an action that improves health outcomes. If women with moderate-risk variants or empirically elevated risk do not consistently complete recommended imaging, healthcare systems may need stronger follow-up mechanisms. These could include automated reminders, direct scheduling, navigation by genetic counselors, coordination between testing laboratories and clinics, and clearer explanations of why both mammography and MRI may be recommended. The results also highlight the importance of distinguishing moderate risk from average risk without minimizing the significance of either category.

The study also underscores the need for caution when interpreting screening adherence as a measure of patient motivation. Missed or delayed examinations may reflect structural obstacles rather than a lack of concern. Insurance coverage for MRI differs across jurisdictions and plans, and the requirements for prior authorization can be difficult to navigate. Transportation, work schedules, caregiving responsibilities and fear of false-positive results may all influence attendance. Researchers and clinicians must also account for differences in how adherence is measured, including whether a woman completes imaging within a narrow annual window or within a broader interval. These technical details can substantially change the apparent level of compliance.

As genetic testing expands, the number of people receiving results that fall between clearly low and clearly high risk will continue to grow. Moderate-risk genes create one of the most demanding categories for clinical communication because their effects are meaningful but variable. The new analysis suggests that the next frontier of hereditary cancer care is not simply finding more variants. It is building systems that help patients understand those variants and remain connected to appropriate screening over time. The study’s message is therefore both scientific and operational: identifying risk is only the first step, and the success of precision prevention will ultimately be judged by whether accurate risk information leads to earlier detection and better outcomes.

Subject of Research: Breast cancer screening adherence after multigene panel testing among women with pathogenic variants in moderate-risk genes or empirically increased breast cancer risk.

Article Title: Breast cancer screening adherence after multigene panel testing among women with pathogenic variants in moderate-risk genes or with empirically increased breast cancer risk

Article References: Breast Cancer Research and Treatment, Springer Nature, 2026.

Image Credits: AI Generated

DOI: 10.1007/s10549-026-08020-5

Keywords: breast cancer, genetic testing, multigene panel, pathogenic variants, moderate-risk genes, screening adherence, mammography, breast MRI, hereditary cancer risk, precision medicine

Severe Obesity Severely Limits Participation in Cancer Screening: New Study Reveals Stark Disparities

In a comprehensive cross-sectional analysis published recently in JAMA Network Open, researchers from the Pennington Biomedical Research Center have shed critical light on a troubling correlation between severe obesity and diminished rates of cancer screenings among U.S. adults. The study, titled “Obesity Severity and Cancer Screening in US Adults,” harnessed a vast dataset drawn from the Behavioral Risk Factor Surveillance System (BRFSS), encompassing over two million anonymized profiles stratified by body mass index (BMI). Through rigorous statistical methodologies, the research team established that individuals with a BMI of 50.0 or greater not only face unique physiological challenges but also encounter systemic barriers resulting in significantly lower engagement with recommended cancer screening protocols.

Cancer screenings are cornerstone preventive measures, fundamental in the early detection and treatment of malignancies including colorectal, cervical, breast, and prostate cancers. These interventions have a proven record of reducing cancer morbidity and mortality. Despite such benefits, the new findings illuminate a clear disparity in screening adherence within populations experiencing severe obesity—a demographic often underrepresented in clinical preventive care metrics. The researchers identified marked reductions in screening rates for Papanicolaou tests (Pap smear), mammography, sigmoidoscopy, and colonoscopy for those in the highest BMI bracket compared to the normative BMI reference group of 18.5 to 29.9.

This disparity suggests the interplay of multifactorial obstacles. Dr. Vance Albaugh, Assistant Professor of Metabolic Surgery at Pennington Biomedical and affiliated with the Metamor Institute, points out, “Our findings highlight an urgent and overlooked gap in healthcare delivery. Individuals with severe obesity face not only anatomical and technical challenges but also accessibility issues within the current clinical infrastructure.” He further elaborates that conventional screening methods often require specialized equipment and accommodations rarely available or routinely implemented in healthcare settings serving this population.

The study’s methodology was robust, excluding profiles lacking precise BMI data to maintain cohort integrity. The final dataset was stratified into distinct BMI categories: 30.0 to 34.9, 35.0 to 39.9, 40.0 to 49.9, exceeding 50.0, and a reference group with BMI ranging from 18.5 to 29.9. This granular approach enabled a nuanced understanding of how cancer screening uptake varies not just with obesity presence but with its severity. Interestingly, the categories representing mild to moderate obesity (BMI 30.0 to 39.9) exhibited similar or marginally increased screening rates relative to the reference group. This suggests that individuals within these ranges might maintain better healthcare engagement or experience fewer impediments than those with extreme obesity levels.

Technical limitations further compound these challenges. Standard screening devices and protocols are often calibrated for average body sizes, leading to potential inaccuracies or discomfort when applied to severely obese individuals. For instance, mammography can be technically arduous as standard mammography machines may fail to accommodate large breast volumes adequately, potentially resulting in incomplete imaging or misdiagnosis. Colonoscopy, a highly effective diagnostic follow-up for colorectal screening tests, is similarly complicated by procedural risks and technical difficulties associated with body habitus extremes. Consequently, providers may be reluctant to recommend or perform such screenings, inadvertently perpetuating underdiagnosis in this vulnerable group.

Emerging self-administered, home-based cancer screening modalities offer some hope. Tests such as fecal immunochemical tests (FIT) and HPV self-swabs reduce reliance on clinical visits and could theoretically increase screening adherence among populations facing physical or systemic barriers. However, as Dr. Albaugh cautions, “While promising, these home-based tests depend heavily on appropriate clinical follow-up. For example, a positive FIT necessitates colonoscopy for definitive evaluation, underscoring the need for integrated care pathways robust enough to support these patients beyond initial testing.”

The research underscores a critical need for research and policy initiatives targeted at optimizing cancer screening accessibility and effectiveness for severely obese individuals. Designing and implementing adaptive screening technologies, improving provider training on obesity-related healthcare delivery, and expanding healthcare system capacity to appropriately accommodate and support these patients are paramount goals. Moreover, targeted public health campaigns are necessary to raise awareness among patients and providers alike regarding the heightened risks and screening importance within this demographic.

Dr. John Kirwan, Executive Director of Pennington Biomedical, emphasized the broader implications of these findings: “This study not only delineates a concerning healthcare disparity but also serves as a call to action. We must intensify efforts to understand the root barriers—be they physical, psychosocial, or systemic—that inhibit screening participation in those with severe obesity. Early detection remains our best weapon against cancer, and equitable access to these preventive services is a foundational healthcare right.”

The Pennington Biomedical Research Center continues to lead pioneering work examining the interrelations between metabolic health disorders and chronic disease risk factors. With a research enterprise supported by over 600 staff and a network of specialized clinics and laboratories, the Center is uniquely positioned to catalyze innovations that span molecular science to societal health interventions. This latest investigation contributes a vital piece to the complex puzzle of how obesity severity modulates health outcomes and healthcare utilization.

As the prevalence of severe obesity rises in the United States, with significant implications for public health, addressing gaps in preventive care becomes even more urgent. By enhancing cancer screening frameworks to accommodate anatomical differences and removing logistical barriers, the healthcare system can progress toward reducing cancer-associated morbidity and mortality in this high-risk group. The study’s revelations impel clinicians, researchers, policymakers, and patient advocates to convene interdisciplinary strategies aimed at bridging these gaps.

In conclusion, the Pennington Biomedical study provides a compelling evidentiary basis underscoring severe obesity as a negative determinant of cancer screening compliance. Overcoming these disparities requires innovation in both clinical technology and healthcare delivery models, alongside intensified patient engagement and education efforts. The goal remains unequivocal: ensuring all individuals, irrespective of BMI, receive timely, efficacious cancer screening and thereby improving early detection and survival outcomes nationwide.

Subject of Research: People

Article Title: Obesity Severity and Cancer Screening in US Adults

News Publication Date: September 22, 2025

Web References: www.pbrc.edu

References: Published in JAMA Network Open on 17-Sep-2025, DOI: 10.1001/jamanetworkopen.2025.32402

Keywords: Cancer screening, Obesity, Preventive care, Metabolic health, Colorectal cancer, Breast cancer, Cervical cancer